Test a lab treatment for ROSAH syndrome using blood cells
This trial studies DF-003 in lab tests using blood immune cells taken from people with ROSAH syndrome. It aims to see whether the treatment works in lab “ex vivo” tests and could guide future options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have ROSAH syndrome with the confirmed T237M genetic mutation
- You must be able to give consent (or have it given appropriately)
- You should not be in an emergency situation
- You must not have HIV or hepatitis B or hepatitis C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called DF-003 for people with ROSAH syndrome who have eye inflammation (uveitis). The goal is to see if the drug is safe and tolerable. It might help reduce eye inflammation and other symptoms.
This trial compares how well different forms of an experimental drug are absorbed by the body. Healthy volunteers will receive the drug and have blood tests to see which version works best.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
This early-phase trial tests whether a new type of immune cell (CAR NK) can treat two conditions: antisynthetase antibody syndrome (a rare autoimmune disease) and rheumatoid arthritis. It's for people whose current treatments haven't worked well enough.
This trial tests an experimental medicine called REGN17235 to see if it is safe and tolerable for people with certain blood conditions, specifically low-risk MDS or CCUS with a specific gene change (SF3B1 mutation). It aims to help improve blood cell production and reduce symptoms.
This study tests an experimental RNA-based medicine (AIR-001) for people with a genetic form of alpha-1 antitrypsin deficiency (AATD). It aims to see if the drug can help boost your body's own protective protein levels and may slow lung damage.
Hear when a new Unrecognized Condition trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.